EUVIMEDΑνακαλύψτε το EUVIMED
Crossref

Amyloidosis and Heart Transplantation in a New Era

Melissa A Lyle iD, Juan Maria M Farina, Erin Wiedmeier-Nutor, Vanda Lindpere iD, Molly Klanderman, Jose N Nativi-Nicolau, Juan Carlos Leoni Moreno, Rohan M Goswami iD, Daniel S Yip, Parag C Patel, Taimur Sher, Andrew N Rosenbaum and 13 more

Clinical Transplantation · 2025

DOI: 10.1111/ctr.70070 ↗

At a glance

Journal article in Clinical Transplantation, 2025. Written by Melissa A Lyle and 24 co-authors. Institution: Department of Transplantation, Division of Advanced Heart Failure and Transplant, Mayo Clinic in Florida, Jacksonville, Florida, USA. Major MEDLINE topics: Heart Transplantation, Amyloidosis. Cited 11 times so far (Crossref); 38 references.

ΠερίληψηSubjectsΒιβλιογραφικά στοιχείαCiteRelated studies

Abstract (original language)

Background

The prognosis in patients with advanced cardiac amyloidosis (CA) remains poor.

Objectives

We sought to describe survival post heart transplantation (HT) in amyloid compared with non‐amyloid recipients, highlight waitlist times within the new allocation system across three Organ Procurement and Transplantation Network (OPTN) regions, and describe multiorgan transplantation (MOT) in hereditary amyloidosis.

Methods

This is a retrospective review of end‐stage CA patients who underwent HT at Mayo Clinic from January 2007 to December 2020. Wait time was compared in the new versus old OPTN allocation era starting December 18, 2018 by Wilcoxon rank sum test. All‐cause mortality for those with and without CA was compared using Kaplan–Meier estimates with log rank analysis, censoring December 16, 2022.

Results

Fifty‐five patients with CA underwent HT between 2007 and 2020, 8 light chain amyloidosis (AL) (14.5%), 28 hereditary transthyretin (ATTRv) (50.9%), 17 wildtype transthyretin (ATTRwt) (30.9%), and 2 hereditary apolipoprotein A1 (AApoA1) amyloidosis patients (3.6%). No significant difference in overall survival post‐transplant was seen in amyloid compared with non‐amyloid ( p = 0.816). Median time to HT was shorter in the new system, 45 days (IQR 24, 78) versus 174 days (IQR 76.5, 483.5), p = 0.006. There was a decline in MOT in hereditary amyloidosis over time with the concomitant rise in disease‐targeted therapies.

Conclusions

HT survival in CA patients was similar to non‐amyloid patients. The new allocation system benefits this cohort with shorter wait times. There is less MOT in hereditary amyloidosis with increased utilization of disease‐targeted therapy.

Subjects

MeSH terms (MEDLINE)

Heart TransplantationAmyloidosisHumansMaleFemaleRetrospective StudiesMiddle AgedPrognosisFollow-Up StudiesSurvival RateWaiting ListsTissue and Organ ProcurementAgedCardiomyopathiesAdult

Author keywords

cardiac amyloidosisheart transplantationmultiorgan transplantationsurvival

Authors and institutions

  • Department of Transplantation, Division of Advanced Heart Failure and Transplant, Mayo Clinic in Florida, Jacksonville, Florida, USA.
  • Department of Cardiovascular Medicine, Mayo Clinic in Arizona, Scottsdale, Arizona, USA.
  • Department of Hematology, Mayo Clinic in Arizona, Scottsdale, Arizona, USA.
  • Department of Quantitative Health Sciences, Division of Clinical Trials and Biostatistics, Mayo Clinic in Arizona, Scottsdale, Arizona, USA.
  • Division of Hematology and Oncology, Mayo Clinic in Florida, Jacksonville, Florida, USA.
  • Department of Cardiovascular Medicine, Mayo Clinic in Minnesota, Rochester, New York, USA.

ORCID profiles: Melissa A Lyle, Vanda Lindpere, Rohan M Goswami, Julie L Rosenthal

Cite

APA

Lyle, M. A., Farina, J. M. M., Wiedmeier-Nutor, E., Lindpere, V., Klanderman, M., Nativi-Nicolau, J. N., Leoni Moreno, J. C., Goswami, R. M., Yip, D. S., Patel, P. C., Sher, T., Rosenbaum, A. N., AbouEzzeddine, O. F., Boilson, B. A., Kushwaha, S. S., Clavell, A. L., Steidley, D. E., Hardaway, B. W., Scott, R. L., …, & Rosenthal, J. L. (2025). Amyloidosis and Heart Transplantation in a New Era. Clinical Transplantation. https://doi.org/10.1111/ctr.70070

Vancouver

Lyle MA, Farina JMM, Wiedmeier-Nutor E, Lindpere V, Klanderman M, Nativi-Nicolau JN, et al. Amyloidosis and Heart Transplantation in a New Era. Clinical Transplantation. 2025. doi:10.1111/ctr.70070

BibTeX
@article{Lyle2025,
  author = {Lyle, Melissa A and Farina, Juan Maria M and Wiedmeier-Nutor, Erin and Lindpere, Vanda and Klanderman, Molly and Nativi-Nicolau, Jose N and Leoni Moreno, Juan Carlos and Goswami, Rohan M and Yip, Daniel S and Patel, Parag C and Sher, Taimur and Rosenbaum, Andrew N and AbouEzzeddine, Omar F and Boilson, Barry A and Kushwaha, Sudhir S and Clavell, Alfredo L and Steidley, David E and Hardaway, Brian W and Scott, Robert L and LeMond, Lisa M and Fonseca, Rafael and Gertz, Morie A and Dispenzieri, Angela and Grogan, Martha and Rosenthal, Julie L},
  title = {Amyloidosis and Heart Transplantation in a New Era},
  journal = {Clinical Transplantation},
  year = {2025},
  doi = {10.1111/ctr.70070}
}
Start for free →